Shionogi, Nippon Kayaku to Release Cetrotide.Tokyo, Japan, Sept 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shionogi & Co., Ltd. and Nippon Kayaku Co., Ltd. today announced the release of Cetrotide (generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : Cetrorelix acetate), indicated for the prevention of premature ovulation ovulation /ovu·la·tion/ (ov?u-la´shun) the discharge of a secondary oocyte from a graafian follicle.ov´ulatory o·vu·la·tion n. The discharge of an ovum from the ovary. . Cetrotide was developed by Zentaris GmbH, a wholly-owned subsidiary of Canadian AEterna Zentaris Inc. The drug has been approved by over 93 countries in the world. Cetrotide is the first drug of its kind to be approved for clinical purposes when it received manufacturing and distribution approval in Japan on April 20. However, it is not covered not covered Health care adjective Referring to a procedure, test or other health service to which a policy holder or insurance beneficiary is not entitled under the terms of the policy or payment system–eg, Medicare. Cf Covered. by health insurance since fertility treatment is not covered in Japan. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion